FLEXcyte 96 Grant

FLEXcyte 96 – Call for Proposals

Analyze the contractility of your human iPSC-derived cardiomyocytes or other contractile cells in vitro: The FLEXcyte 96 technology utilizes a disposable unique 96-well plate with incorporated 10 µm polydimethylsiloxane (PDMS) membranes (FLX-96 plates): The cells adhere as monolayers on the flexible substrate. This unique technology allows for recordings in a native-like environment.

Principle: The contractility is measured via movement of the utilized PDMS membranes: While being deflected by the weight of the culture medium, rhythmic contraction of the contractile cells (e.g. cardiomyocytes) lift the membranes in the 96-well upwards. By measuring the changes in deflection, the mechanical stress can be calculated. 

Nanion Technologies GmbH will provide a complete instrument for a 6-month project and an intense training on the method and innoVitro GmbH will provide a bundle of consumables. Furthermore, Nanion and innoVitro scientists will support the project intensely.

Projects considered for sponsorship are the development of a new FLEXcyte-based assays or a scientific question concerning structural and functional contractility recordings in cardiotoxicity, safety and efficacy screening and basic research.

"We were very pleased with our choice to engage innoVitro’s contractility service. The studies using human iPSC-derived cardiomyocytes were tailored to our needs to provide results comparable to already existing (in house) data and the fast execution followed by a comprehensive study report completed the service perfectly."

Nina Glaser,
Head of Early Safety Electrophysiology,
Merck Healthcare KGaA